Mesoblast Ltd ADR MESO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $14.32
- Day Range
- $14.01–14.34
- 52-Week Range
- $13.05–21.50
- Bid/Ask
- $14.03 / $16.92
- Shares Outstanding
- 129.85M
- Market Cap
- $1.83B
- Volume/Avg
- 265,207 / 231,953
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 15.16
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 108
- Website
- https://www.mesoblast.com
Valuation
|
Metric
|
MESO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.21 |
Price/Sales | 15.16 |
Price/Cash Flow | — |
Price/Earnings
MESO
Financial Strength
|
Metric
|
MESO
|
|---|---|
Quick Ratio | 1.30 |
Current Ratio | 2.43 |
Interest Coverage | −2.06 |
Quick Ratio
MESO
Profitability
|
Metric
|
MESO
|
|---|---|
Return on Assets (Normalized) | −8.38% |
Return on Equity (Normalized) | −11.27% |
Return on Invested Capital (Normalized) | −7.63% |
Return on Assets
MESO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^%<>Tg | LOCK|&%$< | $128B | |||
| Moderna Inc
MRNA
| LOCK|Q<T^&@& | LOCK|?bl | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Z>&LV< | LOCK|JK&?D | $76B | |||
| argenx SE ADR
ARGX
| LOCK|y^#LH>K | LOCK|n> | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#tL$>s | LOCK|Zh | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$>CZ<& | LOCK|k?GP^ | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|X#$?Nz@ | LOCK|b>&% | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|wCyW<Q< | LOCK|T@ | $24B | |||
| Incyte Corp
INCY
| LOCK|#CJNQTz | LOCK|#t | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|H^W?$^& | LOCK|@& | $15B |
United States